Results 21 to 30 of about 64,621 (307)
Anaplastic carcinoma of pancreas (ACP) are rare pancreatic neoplasms. They are well known to be associated with more aggressive tumor behavior and less favorable prognosis than usual pancreatic ductal adenocarcinoma.
Md Ali Osama, Pooja Bakshi, Kusum Verma
doaj +1 more source
Repeated pancreatectomy for pancreatic carcinoma is extremely rare. We report two such patients who underwent pancreatectomy for carcinoma developing in the pancreatic remnant after pylorus-preserving pancreatoduodenectomy (PpPD) for invasive pancreatic ...
Toshitatsu Ogino +7 more
doaj +1 more source
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma [PDF]
Aims: To clarify MUC1 patterns in invasive ductal breast carcinoma and to relate them to clinicopathological parameters, coexpression of other biological markers and prognosis.
de Bock, G. H. +10 more
core +1 more source
Multidisciplinary Approach to a Patient with Acinar Cell Carcinoma, a Rare Pancreatic Malignancy
Acinar cell carcinoma (ACC) of the pancreas is a relatively rare malignant neoplasm that constitutes about 1% of all pancreatic exocrine tumors. The disease is generally managed similarly as pancreatic ductal adenocarcinoma (PDAC), with surgical ...
Maria Celeste Palmarocchi +3 more
doaj +2 more sources
The common presenting symptoms of pancreatic cancer are abdominal pain, weight loss, and jaundice. Pancreatic adenocarcinoma presenting with diabetic ketoacidosis is a very rare emergent clinical condition.
Tezcan Kaya +4 more
doaj +1 more source
Pancreatic colloid carcinoma is an uncommon and unique malignancy possessing a significantly more favorable prognosis than that of ordinary pancreatic ductal adenocarcinoma. Accurate diagnosis of this rare entity is thus important for leading the ensuing
Chuan-Han Chen, Hong-Zen Yeh, Hsin-Ni Li
doaj +1 more source
Challenges of drug resistance in the management of pancreatic cancer [PDF]
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Naomi Walsh +10 more
core +1 more source
Background There are many reports of port site recurrence after laparoscopic surgery for various types of cancer. However, only two cases of port site recurrence after laparoscopic pancreatectomy have been reported to date.
Takashi Aida +7 more
doaj +1 more source
Mixed pancreatic acinar cell-ductal adenocarcinoma: Complexities in diagnosis and treatment
Background: Acinar cell carcinoma of the pancreas (ACC) is a rare malignancy, accounting for approximately 1-2% of all pancreatic cancers. Up to a quarter of ACCs are estimated to contain a significant component of another histology such as ...
Abdullah Nasser +4 more
doaj +1 more source
Ca2+ Signaling and Its Potential Targeting in Pancreatic Ductal Carcinoma [PDF]
Pancreatic cancer (PC) is a major cause of cancer-associated mortality in Western countries (and estimated to be the second cause of cancer deaths by 2030). The main form of PC is pancreatic adenocarcinoma, which is the fourth most common cause of cancer-related death, and this situation has remained virtually unchanged for several decades.
Bettaieb, Louay +20 more
openaire +2 more sources

